|1.||Nemoto, Kyuichi: 3 articles (01/2011 - 01/2006)|
|2.||Birck, Rainer: 3 articles (01/2006 - 02/2003)|
|3.||Schmitt, Wilhelm H: 2 articles (01/2011 - 06/2005)|
|4.||Heinzel, Peter A: 2 articles (01/2011 - 06/2005)|
|5.||Saiga, Kan: 2 articles (07/2010 - 05/2002)|
|6.||Jayne, David R W: 2 articles (03/2010 - 09/2008)|
|7.||Flossmann, Oliver: 2 articles (03/2010 - 09/2008)|
|8.||Nemoto, K: 2 articles (07/2009 - 12/2006)|
|9.||Hellmich, B: 2 articles (07/2009 - 12/2005)|
|10.||van der Woude, Fokko J: 2 articles (01/2006 - 06/2005)|
|1.||Wegener Granulomatosis (Wegener's Granulomatosis)
06/01/2005 - "Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients."
03/01/2010 - "Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin."
07/01/2009 - "Deoxyspergualin in relapsing and refractory Wegener's granulomatosis."
03/01/2009 - "Polyamine compound deoxyspergualin (DSG) is a potent immunosuppressive agent that has been applied clinically for protecting graft rejection and treatment of Wegener's granulomatosis. "
12/01/2006 - "15-Deoxyspergualin (DSG) is an alternative treatment modality for Wegener's granulomatosis (WG) patients refractory to conventional treatment. "
|2.||Autoimmune Diseases (Autoimmune Disease)
09/01/1995 - "Deoxyspergualin (DSG) is a potent immunosuppressive agent that is currently undergoing clinical trials for treatment of transplant rejection, preventive of human anti-mouse Ab response, and blocking autoimmune disease progression. "
06/23/1993 - "Preclinical studies with 15-deoxyspergualin in various animal models for autoimmune diseases."
01/01/1993 - "Immunosuppressive therapy of organ-specific nephritic autoimmune diseases with 15-deoxyspergualin."
09/01/1991 - "15-Deoxyspergualin (15-DOS) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice."
09/01/1988 - "Biological activities of deoxyspergualin in autoimmune disease mice."
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
02/01/1999 - "Inhibitory effect of 15-deoxyspergualin on coronary arteriosclerosis in the transplanted heart."
09/01/1994 - "Effects of cyclosporine and 15-deoxyspergualin on coronary arteriosclerosis after heart transplantation in the rat."
09/01/1994 - "We concluded that 15-Deoxyspergualin is superior to cyclosporine in preventing graft coronary arteriosclerosis after heart transplantation."
09/01/1994 - "The purpose of this study was to evaluate the effects of 15-Deoxyspergualin on graft coronary arteriosclerosis after heterotopic heart transplantation in a rat model and compare the effects to those of cyclosporine treatment. "
10/01/1993 - "The purpose of this study is to evaluate the effects of Cyclosporine (CsA), FK-506 (FK) and 15-Deoxyspergualin (DOS) on coronary arteriosclerosis after rat heart transplantation. "
11/01/1999 - "Immunosuppressive effect of deoxyspergualin in proliferative glomerulonephritis."
01/01/1999 - "[Effects of deoxyspergualin on proliferative glomerulonephritis]."
05/01/1995 - "It has previously been shown that the immunosuppressive drug deoxyspergualin can inhibit renal injury in experimental glomerulonephritis. "
05/01/1993 - "Suppression of experimental crescentic glomerulonephritis by deoxyspergualin."
10/01/2005 - "Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus."
|5.||Graft vs Host Disease (Graft-Versus-Host Disease)
02/01/1988 - "The efficacy of 15-deoxyspergualin (15-DS) was tested in two models of experimental graft versus host disease (GvHD) in mice. "
09/01/2000 - "Reduced levels of Hsp70 result in a therapeutic effect of 15-deoxyspergualin on acute graft-versus-host disease in (DA x LEW)F1 rats."
11/18/1999 - "A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. "
01/28/1999 - "A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent currently commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. "
05/01/1996 - "The effect of 15-deoxyspergualin (DSG) on bone marrow (BM) engraftment and graft-versus-host disease (GVHD) was studied in mice across both major (MHC) and minor (MiHC) histocompatibility barriers. "
|3.||Immunosuppressive Agents (Immunosuppressants)
|4.||Antineutrophil Cytoplasmic Antibodies (ANCA)
|5.||mycophenolate mofetil (Cellcept)
|2.||Heart Transplantation (Grafting, Heart)
|3.||Transplantation (Transplant Recipients)